CytoDyn Announces Webcast to Provide Company Update
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will host an investment community webcast to provide a Company update on Thursday, December 14, 2023. The Company update will include discussion about recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the Company’s next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.
Related news for (CYDY)
- CytoDyn Releases ESMO Breast Cancer Meeting Poster
- CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
- CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
- CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
- CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab